Let us advance cancer therapies together
Join us at AACR 2025 to explore how Champions Oncology’s in vivo, ex vivo platforms, and clinical specialty testing services can fast-track your cancer drug development.
Champions' team of expert scientists are presenting 16 novel research posters at the 2025 annual meeting. Discover how our innovative oncology services portfolio can support your research and upcoming clinical trials. To plan your meeting, you can download and save each poster's schedule to your calendar. The posters will be available for download after the conference.
Sunday - April 27, 2025
#928: Advancing CAR-Ts and anti-immunosuppressive therapy development: Immunosuppressive TME 3D co-culture platform grounded on a fully characterized PDX tumor Bank
Monday - April 28, 2025
#1287: Clinical relevance and translatability of NSCLC patient-derived xenograft (PDX) models for evaluating cMET-targeted therapies
#1228: High throughput phenotyping and drug discovery using the TumorGraft3D co-culture platform and flow cytometry
#1827: Investigating the efficacy of 177-Lu therapeutics in a series of Castrate Resistant Prostate Cancer PDX Models
#2849: Comparative analysis of mutational signatures in TumorGraft PDX bank and TCGA dataset to improve patient tumor modeling
#3717: A Digital Patient & Simulated Clinical Trial of Cytarabine Treatment
Tuesday - April 29, 2025
#3903: Multi-omics and histological assessment to identify patient-derived xenograft models of invasive lobular carcinoma
#4007: Building 3D ex vivo models as a powerful platform for anti-cancer drug and biomarker discovery
#4006: HER2-positive patient-derived xenograft organoids (PDXOs) as a novel preclinical tool to evaluate new therapies against HER2-driven cancers
#3993: High-throughput screening of clinically relevant patient-derived 3D cultures to inform on the efficacy of Antibody Drug Conjugate Payloads in 10 distinct cancer indications
#3931: Establishment of an orthotopic intracranial luciferase labelled patient-derived xenograft of glioblastoma in immunocompromised mice model
#6275 Predicting clinical checkpoint inhibitor responses with TumorGraft3D PBMC co-culture
#5567: Targeted immunotherapies in Multiple Myeloma: focus on flow cytometry markers and therapeutic implications
Wednesday - April 30, 2025
#6851: An integrated preclinical platform for Antibody-Drug Conjugate development
#7281: Leveraging the tumor microenvironment (TME) atlas to identify the best PDX model for pre-clinical testing of TME targeting agents
#7282: Development of an HLA-matched humanized immune system mouse model with primary AML patient samples for immunotherapy testing
Book a Meeting with Leading Experts
Meet Dr. Shankar Vallabhajosula, a recognized leader in Radiochemistry and Radiopharmacy, and Dr. Steffi Oesterreich, an expert in Breast Cancer research, at our booth. Engage with these key opinion leaders and the Champions team to explore strategies and solutions for your cancer drug development project. Contact us today to book a meeting.
Dr. Steffi Oesterreich is a leading expert in breast cancer research, with a particular focus on invasive lobular carcinoma (ILC), a common yet understudied breast cancer subtype. Her work aims to advance the understanding of breast cancer development and progression to improve patient outcomes. Using genetic and epigenetic analyses, cell line and animal models, and clinical samples, her research explores the mechanisms driving disease progression. Currently, her team is investigating estrogen receptor (ER) mutations, which occur in 20-40% of metastatic ILC cases, to develop targeted therapeutic strategies for overcoming resistance and improving endocrine therapy efficacy.
Dr. Shankar Vallabhajosula is a distinguished expert in radiochemistry and radiopharmacy with over four decades of experience in nuclear medicine. He earned his Ph.D. from the University of Southern California and has held academic positions at Mount Sinai Medical Center and Weill Cornell Medicine, where he is now Professor Emeritus. Dr. Vallabhajosula has authored over 130 publications and played a key role in developing more than 30 investigational radiopharmaceuticals, including [18F]FDG. A recipient of multiple awards, he continues to advance radiopharmaceutical sciences in both academic and industry settings.
